Integer (NYSE:ITGR) Shares Gap Down to $123.27

Shares of Integer Holdings Co. (NYSE:ITGR) gapped down prior to trading on Thursday . The stock had previously closed at $123.27, but opened at $114.00. Integer shares last traded at $112.86, with a volume of 342,010 shares traded.

Analyst Ratings Changes

ITGR has been the subject of a number of research reports. KeyCorp raised their price objective on Integer from $123.00 to $139.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 9th. CL King initiated coverage on Integer in a research report on Thursday, March 14th. They issued a “buy” rating and a $137.00 price objective for the company. Bank of America upgraded Integer from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $105.00 to $135.00 in a research report on Monday, April 15th. Finally, Benchmark restated a “buy” rating and set a $130.00 target price on shares of Integer in a research report on Friday. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $120.50.

Integer Price Performance

The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.71 and a current ratio of 2.80. The firm has a market cap of $3.67 billion, a P/E ratio of 40.74, a P/E/G ratio of 1.71 and a beta of 1.10. The company has a 50-day moving average of $113.11 and a 200 day moving average of $99.78.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.02. Integer had a return on equity of 10.80% and a net margin of 5.68%. The firm had revenue of $414.80 million during the quarter, compared to the consensus estimate of $412.78 million. During the same quarter in the previous year, the company posted $0.87 EPS. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Integer Holdings Co. will post 5.31 EPS for the current year.

Institutional Investors Weigh In On Integer

Several hedge funds and other institutional investors have recently made changes to their positions in ITGR. SG Americas Securities LLC increased its stake in shares of Integer by 2,037.3% in the 3rd quarter. SG Americas Securities LLC now owns 26,289 shares of the medical equipment provider’s stock valued at $2,062,000 after buying an additional 25,059 shares during the period. Raymond James & Associates increased its stake in shares of Integer by 4.0% in the 3rd quarter. Raymond James & Associates now owns 40,700 shares of the medical equipment provider’s stock valued at $3,192,000 after buying an additional 1,564 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Integer by 16.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,902 shares of the medical equipment provider’s stock valued at $384,000 after buying an additional 684 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Integer by 2.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,489 shares of the medical equipment provider’s stock valued at $1,293,000 after buying an additional 353 shares during the period. Finally, Park Avenue Securities LLC acquired a new stake in shares of Integer in the 3rd quarter valued at $462,000. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.